Volker Budach

With decades of leadership in radiation oncology, Volker Budach served as Clinic Director of the Charité Clinic for Radiation Oncology until 2022 and now works as a specialist at RadioOnkologie im Vosspalais. His clinical priorities include head and neck tumors, sarcomas, and breast carcinomas, shaped by years of scientific and clinical work. In practice, he is involved in treatment planning that balances oncological safety with patient-specific functional outcomes. For patients who need alternatives to standard chemotherapy, he also supports radioimmunotherapy with cetuximab when cisplatin, 5-FU, or mitomycin C are contraindicated.

At the clinic, the work is grounded in structured, evidence-based radiation oncology. Primary radiochemotherapy is delivered as several weeks of daily radiotherapy, with attention to the typical acute reactions and the potential for late side effects such as dry mouth and dental caries sensitivity. When contraindications exist, radioimmunotherapy with cetuximab can be performed instead of chemo-radiation.

Education

• 1980-1985 — Specialist training for diagnostic radiology and radiation therapy, University Hospital Essen.
• 1985 — Specialist certification in radiation therapy.

Work experience

• 1980-1985 — Resident doctor; specialist training for diagnostic radiology and radiation therapy, University Hospital Essen.
• 1985-1993 — Senior Physician at the Clinic for Radiation Oncology and Radiation Therapy, University Clinic Essen; West German Tumor Center.
• 1993 — Called for a W3 professorship at Charité (Berlin) and appointed Clinic Director at Charité sites (CCM mentioned).
• Until 2022 — Clinic Director of the Charité Clinic for Radiation Oncology.
• 2022-present — Physician at RadioOnkologie im Vosspalais (Berlin Mitte).

Clinical focus and techniques

Budach’s radiation oncology practice focuses on oncological treatment strategies for solid tumors, with specific emphasis on head and neck tumors, sarcomas, and breast carcinomas. He works with multimodal concepts where radiotherapy is paired with systemic therapy when appropriate.

• Primary radiochemotherapy with daily radiotherapy over several weeks.
• Radioimmunotherapy with cetuximab as an alternative when contraindications to cisplatin, 5-FU, or mitomycin C exist.

Professional societies and certifications

• DEGRO — German Society for Radiation Oncology.
• ARO.
• DKG.
• AGO.
• ESTRO.
• ESGO.
• ASTRO.
• ASCO.
• ESHO.
• EORTC.

Academic output

He has acquired, managed, and published several scientific studies funded by the German Cancer Aid, with clinical and scientific focus on therapy for head and neck tumors, sarcomas, and breast carcinomas.

Courses and advanced training

• Not specified in the provided evidence.

Awards and recognition

• Not specified in the provided evidence.

At RadioOnkologie im Vosspalais in Berlin, Budach’s work supports international patients seeking radiation oncology consultations and second opinions. The clinic is based in Germany, and the team’s private-practice model is designed for patient-oriented, holistic care. For treatment planning discussions, patients can request an appointment through the clinic’s contact pathway.